Показати простий запис статті
dc.contributor.author |
Lukyanova, N.Yu. |
|
dc.contributor.author |
Rusetskya, N.V. |
|
dc.contributor.author |
Tregubova, N.A. |
|
dc.contributor.author |
Chekhun, V.F. |
|
dc.date.accessioned |
2018-06-15T14:03:43Z |
|
dc.date.available |
2018-06-15T14:03:43Z |
|
dc.date.issued |
2009 |
|
dc.identifier.citation |
Molecular profile and cell cycle in mcf-7 cells resistant to cisplatin and doxorubicin / N.Yu. Lukyanova, N.V. Rusetskya, N.A. Tregubova, V.F. Chekhun // Experimental Oncology. — 2009. — Т. 31, № 2. — С. 87–91. — Бібліогр.: 26 назв. — англ. |
uk_UA |
dc.identifier.issn |
1812-9269 |
|
dc.identifier.uri |
http://dspace.nbuv.gov.ua/handle/123456789/135701 |
|
dc.description.abstract |
Aim: To compare ultrastructure, phenotypic profile and cell cycle progression ofMCF-7 human breast cancer cells and MCF7 sublines
resistant to cisplatin (MCF-7/DDP) and doxorubicin (MCF-7/DOX). Methods: MTT-test, immunocytochemistry, flow
cytometry, electron microscopy. Results: The development of drug resistance to cisplatin and doxorubicin in MCF-7 cells upon the
culturing of the initial cells with the raising concentrations of cytostatics was accompanied by the increase in cells adhesion, the
increasing differentiation grade and the loss of steroid hormone receptors. Besides, it was shown that antiapoptotic mechanisms
(decrease ofBcl-2 expression) and intracellular glutathione detoxifying system are involved in the process of cisplatin resistance development
inMCF-7 cells. Atthe same time, P-glycoprotein overexpression in cells resistant to doxorubicin suggests MDR-dependent
mechanism. Both doxorubicin- and cisplatin-resistant cells are characterized by the changes in the expression of several cell cycle
regulators — Ki-67, cyclin D1, pRb and р21). Conclusion: The long-time culture of MCF-7 cells with cytostatic drugs results
in the decreased cyclin D1, pRb, and Ki-67 expression and increased р21 expression with the increasing differentiation grade of the
resistant cells. The underlying mechanisms of resistance to cisplatin and doxorubicin in MCF-7 cells may be different. |
uk_UA |
dc.description.sponsorship |
This work was supported by Fundamental researches
state foundation (№ F28.4/047). We gratefully
acknowledge Phd.M.P. Zavelevich (R.E. Kavetsky
Institute of Experimental Pathology, Oncology and
Radiobiology) for his helpful advice. |
uk_UA |
dc.language.iso |
en |
uk_UA |
dc.publisher |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
uk_UA |
dc.relation.ispartof |
Experimental Oncology |
|
dc.subject |
Original contributions |
uk_UA |
dc.title |
Molecular profile and cell cycle in mcf-7 cells resistant to cisplatin and doxorubicin |
uk_UA |
dc.type |
Article |
uk_UA |
dc.status |
published earlier |
uk_UA |
Файли у цій статті
Ця стаття з'являється у наступних колекціях
Показати простий запис статті